


RUMBA's week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/F/TAF.



Sophie Degroote¹, Evy Blomme², Liesbeth Delesie¹,
Linos Vandekerckhove^{1,2}, Marie-Angélique De Scheerder¹

¹University Hospital Ghent, Ghent, Belgium,

²HIV Cure Research Center, Ghent University, Ghent, Belgium



BACKGROUND

The logo for the TANGO study, featuring the word "TANGO" in red and blue letters with a circular arrow icon.

Other switch-studies show non-inferior virological efficacy of DTG/3TC versus 3/4 drug regimens as well as its safety and tolerability


The logo for the SALSA study, featuring a stylized figure in red and black with the word "SALSA" in red.

2nd generation integrase inhibitors and tenofovir alafenamide (TAF) have been associated with weight gain

The logo for the PASO DOBLE study, featuring a red heart shape made of dots and the text "PASO DOBLE study".The logo for the DYAD study, featuring the word "DYAD" in red.

RUMBA STUDY

- Phase 4 RCT
- Virologic suppressed participants were 2:1 randomized to switch to DTG/3TC or switch to or stay on B/F/TAF



- Metabolic outcomes as secondary endpoints**
- Differences in metabolic outcomes between **W144** and baseline are reported here

RESULTS

Flow diagram




Baseline characteristics

| | Total (n=130) | | B/F/TAF (n=43) | | DTG/3TC (n=87) | |
|--|---------------|------------|----------------|-----------|----------------|------------|
| Sex, M/F | 118/12 | | 39/4 | | 79/8 | |
| Ethnicity, European/African/ Other | 102/14/14 | | 32/5/6 | | 70/9/8 | |
| Age, y, median (IQR) | 47 | (37-55) | 46 | (38-52) | 48 | (40-56) |
| Time on ART, y, median (IQR) | 7.2 | (4.6-10.8) | 6 | (4.4-9.0) | 8.6 | (5.2-11.5) |
| BMI, kg/m ² , median (IQR) | 25 | (23-28) | 25 | (22-26) | 26 | (23-28) |
| <1y on 2 nd gen INSTI | 15 | | 4 | | 11 | |
| TAF naïve / <1y on TAF | 49/11 | | 21/4 | | 28/7 | |

Previous regimens


DTG/3TC
(n=87)

B/F/TAF
(n=43)



RESULTS


No statistically significant differences were observed between the two arms.



3DR/2DR ratio with 95% CI: 1 [0.96-1.04]

3DR/2DR ratio with 95% CI: 1.04 [0.93-1.16]

3DR/2DR ratio with 95% CI: 0.98 [0.95-1.01]



3DR/2DR ratio with 95% CI: 1.05 [0.99-1.11]

3DR/2DR ratio with 95% CI: 0.93 [0.68-1.25]

3DR/2DR ratio with 95% CI: 1 [0.93-1.08]

RUMBA VERSUS OTHER DTG/3TC TRIALS



PASO DOBLE

n=553

W48: More weight gain in B/F/TAF vs DTG/3TC
(adjusted difference 0.92kg)

Mainly in subgroups switching off ABC or TDF

RUMBA: W48

More increase in fat% in subgroup switching from
ABC/3TC/DTG to B/F/TAF (+4% vs. +1%)

W144: no significant changes

DYAD

n=222

W48: No differences in weight changes between
DTG/3TC and B/F/TAF

Prior regimen: B/F/TAF

RUMBA: subgroup B/F/TAF as baseline regimen:
W48 & W144 no differences in weight changes
between DTG/3TC and B/F/TAF arm

CONCLUSIONS & CONSIDERATIONS



- ▶ RUMBA **week 48** data showed that switching to DTG/3TC had **no impact on the viral reservoir. Metabolic outcomes were comparable** between 2DR and 3DR, with slightly better body composition measures in 2DR [1].
 - ▶ At **week 144**, we confirm **reassuring metabolic outcomes** in both the DTG/3TC and B/F/TAF group. **No statistically significant differences** are found.
-
- ▶ Metabolic outcomes in DTG/3TC switch trials depend on baseline regimen.
 - ▶ Metabolic outcomes should be further investigated to better understand their role and individualize treatment in people with increased risk of metabolic comorbidity.
 - ▶ We await further RUMBA W144 analyses, with multiple imputations based on all intermediate data (week 72, 96 and 120) as well as W240 data.

[1] De Scheerder MA et al. In depth analysis of the HIV reservoir confirms effectiveness and safety of DTG/3TC in a phase 4 randomized controlled switch trial (RUMBA). J Infect Dis. 2024 Sep 3:jiae405. doi: 10.1093/infdis/jiae405. Epub ahead of print. PMID: 39226296.



RUMBA's week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF.



Sophie Degroote¹, Evy Blomme², Liesbeth Delesie¹,
Linus Vandekerckhove^{1,2}, Marie-Angélique De Scheerder¹

¹University Hospital Ghent, Ghent, Belgium,

²HIV Cure Research Center, Ghent University, Ghent, Belgium



Contact: sophie.degroote@uzgent.be